CLDX Stock Overview
A biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Celldex Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$33.47 |
| 52 Week High | US$53.18 |
| 52 Week Low | US$22.11 |
| Beta | 1.6 |
| 1 Month Change | -21.36% |
| 3 Month Change | -33.07% |
| 1 Year Change | -1.59% |
| 3 Year Change | 17.44% |
| 5 Year Change | 1,233.47% |
| Change since IPO | -70.76% |
Recent News & Updates
Recent updates
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth
Jul 07
An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued
Apr 21Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth
Feb 27We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate
Sep 07Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder
Jul 21Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement
Jul 14Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans
May 25Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?
Feb 03Celldex: Pipeline Of Drug Candidates Is Worth A Look
Feb 01Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers
Sep 23We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth
Sep 15Celldex: Powerful Medicines To Yield Further Upsides
Jul 08Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation
May 12We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely
Jan 27
The Celldex Therapeutics (NASDAQ:CLDX) Share Price Is Up 626% And Shareholders Are Delighted
Dec 23Dosing underway in Celldex's CDX-0159 study in skin allergy
Dec 09Shareholder Returns
| CLDX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.3% | -0.4% | -0.6% |
| 1Y | -1.6% | 5.4% | 22.5% |
Return vs Industry: CLDX underperformed the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: CLDX underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| CLDX volatility | |
|---|---|
| CLDX Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CLDX's share price has been volatile over the past 3 months.
Volatility Over Time: CLDX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 160 | Anthony Marucci | www.celldex.com |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity.
Celldex Therapeutics, Inc. Fundamentals Summary
| CLDX fundamental statistics | |
|---|---|
| Market cap | US$2.19b |
| Earnings (TTM) | -US$144.88m |
| Revenue (TTM) | US$6.07m |
363.3x
P/S Ratio-15.2x
P/E RatioIs CLDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLDX income statement (TTM) | |
|---|---|
| Revenue | US$6.07m |
| Cost of Revenue | US$122.87m |
| Gross Profit | -US$116.80m |
| Other Expenses | US$28.07m |
| Earnings | -US$144.88m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.20 |
| Gross Margin | -1,923.62% |
| Net Profit Margin | -2,385.97% |
| Debt/Equity Ratio | 0% |
How did CLDX perform over the long term?
See historical performance and comparison